AstraZeneca and Daiichi Sankyo Report Result of Trastuzumab Deruxtecan in P-II DESTINY-Breast01 Study for HER2 Positive Metastatic Breast Cancer

 AstraZeneca and Daiichi Sankyo Report Result of Trastuzumab Deruxtecan in P-II DESTINY-Breast01 Study for HER2 Positive Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo Report Result of Trastuzumab Deruxtecan in P-II DESTINY-Breast01 Study for HER2 Positive Metastatic Breast Cancer

Shots:

  • The P-II DESTINY-Breast01 study involves assessing of trastuzumab deruxtecan in 184 patients with HER2+ unresectable/ mBC prior treated with trastuzumab emtansine across 100 sites globally
  • The P-II DESTINY- Breast01 study results: ORR (60.9%); DCR (97.3%); mDOR (14.8mos.); mPFS (16.4 mos.); estimated OS @12mos. (86%); safety & tolerability profile is consistent with P-I study
  • Trastuzumab deruxtecan (DS-8201 in the US) is a HER2-targeting ADC, jointly develop & commercialize by AstraZeneca and Daiichi Sankyo globally (Ex-Japan) where Daiichi Sankyo retains exclusive rights for the product. In Oct’2019, the FDA has accepted its BLA and granted PR designation to the therapy

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Delaware Business Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post